In a large US cohort, Lp(a) was assoc w/ #MACE but there was a plateau in risk at the ~70th percentile for those w/ baseline #ASCVD In contrast, those w/out baseline ASCVD, there was a more linear ⬆️ in risk. Thus, the Lp(a) threshold for risk assessment may differ based on

TIMI Talks welcomes its first international guest, Dr. Rasha Al-Lamee of Imperial College London, to discuss angina management and the ORBITA and ORBITA-2 trials Rasha Al-Lamee Nicholas Marston David Berg

In patients with high triglycerides, vupanorsen markedly lowered remnant cholesterol and VLDL-C, positioning ANGPTL3 as a promising target. Now published in the European Journal of Preventive Cardiology: academic.oup.com/eurjpc/advance… TIMI Study Group Nicholas Marston Brian Bergmark

In pts w/elevated triglycerides, vupanorsen, an ANGPTL3 inhibitor, lowered remnant cholesterol by up to 59% & VLDL cholesterol by up to 67% over placebo. ANGPTL3i may be a promising approach for lowering cholesterol on triglyceride-rich lipoproteins doi.org/10.1093/eurjpc…

A focused update to the 2019 NLA scientific statement on use of lipopr... sciencedirect.com/science/articl…. Updated guidance - Measured Lp(a) at least once in all adults! National Lipid Association Marlys Koschinsky Michael Boffa Dave Dixon, Professor & Chair @VCUPharmacy Keith C. Ferdinand, MD, FACC, FAHA, FNLA Erin D. Michos, M.D. Dan Soffer

Happy podcasting anniversary to my #TIMITalks co-host David Berg What better way to celebrate than catching up with Douglas Drachman ahead of #ACC24 See you all in Atlanta! American College of Cardiology

Primary results from Bridge-TIMI 73a Late Breaking Clinical Trial presented by Brian Bergmark at #ACC24 show that #olezarsen reduces #triglyceride levels by ~50% without major safety concerns. Now published in NEJM. Nicholas Marston

In patients with TGs >150 mg/dL and high CV risk, apoC-III inhibitor olezarsen reduced TG levels by ~50%. Olezarsen also reduced apoB and non-HDL-C, markers of atherogenic risk. Proud to be a part of this team. Full paper now in NEJM. TIMI Study Group Brian Bergmark

Big day today for patients with elevated Triglycerides with reduction in apo C-III, TG and pancreatitis. And a double whammy for our group and Ionis. 2 important trials presented and 2 back-to-back NEJM papers!. Big thanks to Brian Bergmark and Erik Stroes. Can it get

I’m honored to work with such an amazing team on this clinically meaningful project. Plus, huge thanks to WIN ADA for the abstract award! Stephen Wiviott Nicholas Marston Giorgio Melloni Filipe A Moura, MD, PhD TIMI Study Group Brigham and Women’s Endocrinology American Diabetes Association - DiabetesPro

In an analysis of five large randomized clinical trials testing established therapies for cardiovascular disease, individuals with clonal hematopoiesis had an increased risk for first but not recurrent myocardial infarction nature.com/articles/s4159…